Browse > Home / Breaking News / Publish the results of phase III studies methylnaltrexone

Publish the results of phase III studies methylnaltrexone

April 28, 2009

The representatives of American pharmaceutical companies Wyeth and Progenics Pharmaceuticals Inc reported that the experimental drug methylnaltrexone for improved promotion intestinal contents in patients with postoperative intestinal obstruction did not show statistically significant results in Phase 1 testing III clinical trials compared to placebo.

Currently, the company Progenics Pharmaceuticals conducted 2 phase III testing of injection drug methylnaltrexone. Analyst investment company Lazard Joule Sendek (Joel Sendek) believes that in this test drugs did not show expected results. This is not the first drugs with which the company Wyeth have problems in the past year. While in February 2008 farmkompaniya received permission of the Control of food and medicines USA (FDA) for use of the drug Pristiq to treat depression, March 12, 2008 by representatives of the European regulatory authorities have reported that Wyeth withdrew from the EMEA for your registration certificate for Pristiq as a drug for the treatment of vasomotor disorders in women in the postmenopausal period in order to conduct additional clinical studies, confirming that the achieved therapeutic effect of drugs exceeds the side effects caused by them

Written by Samanta · Filed Under Breaking News